Aidoc Reports FDA Clears Complete AI Stroke Package

Summation

  • Combined with Aidoc’s previously-cleared AI module for flagging and prioritizing intracranial hemorrhage, together they provide a comprehensive AI package for the identification and triage of both ischemic and hemorrhagic stroke in CTs, speeding time to treatment when every minute counts.
  • Aidoc’s combined stroke solution ensures that the diagnosing facility and the stroke center can work together in a coordinated manner to expedite patient care.
  • Aidoc’s integrated solution provides a single context for radiologists to diagnose both LVO and hemorrhage, so they can quickly decide on the most appropriate course of action.

Aidoc provides AI solutions for radiologists. Today they announced that the US Food and Drug Administration (FDA) has cleared its AI solution for flagging Large-Vessel Occlusion (LVO) in head CTA scans, marking Aidoc’s fourth FDA-cleared AI package.

Combined with Aidoc’s previously-cleared AI module for flagging and prioritizing intracranial hemorrhage, together they provide a comprehensive AI package for the identification and triage of both ischemic and hemorrhagic stroke in CTs, speeding time to treatment when every minute counts.

“Stroke is the ultimate time-critical condition,” said Dr. Marcel Maya, Co-chair Department of Imaging, Cedars-Sinai Medical Center. “The faster we can identify, diagnose and treat it, the better the outcome for patients. Aidoc’s comprehensive stroke package flags both large vessel occlusion and hemorrhages inside our existing workflows, ensuring we can diagnose stroke faster and decide on the best course of treatment. We’re already seeing how this has a positive impact on department efficiency and patient length of stay.”

5% of all deaths in the USA are from stroke, and it is one of the major causes of disability. During a stroke 1.9 million neurons and 14 billion synapses die each minute[1], making fast diagnosis and treatment critical. Improved medical imaging and better treatments have revolutionized stroke care, making it possible to clear occlusions in the brain’s arteries using thrombolysis or mechanical thrombectomy; however, hemorrhage must be ruled out before administering a thrombolytic agent. The faster the time from door-to-treatment for patients suffering from stroke, the more likely a patient will survive without serious neurological impairment.

Aidoc’s always-on solution continuously scans images for both ischemic and hemorrhagic stroke, automatically moving suspected cases to the top of radiologists’ worklists. Aidoc’s integrated solution provides a single context for radiologists to diagnose both LVO and hemorrhage, so they can quickly decide on the most appropriate course of action. Often, patients are diagnosed with stroke in a smaller facility before being moved to a specialist stroke center for treatment. Aidoc’s combined stroke solution ensures that the diagnosing facility and the stroke center can work together in a coordinated manner to expedite patient care.

Research performed by the University of Rochester Medical Center showed Aidoc’s ability to reduce turnaround time for emergency room patients with intracranial hemorrhage by 36.6%. Research by Yale-New Haven Hospital confirmed Aidoc’s impact in expediting the time to treatment for these critical cases.

“With our fourth 501(k) clearance, Aidoc is leading the way in radiology AI with the most comprehensive FDA-cleared AI triage package,” said Gal Yaniv, MD, Endovascular Neurosurgeon, and Neuroradiologist at Sheba Medical Center and Chief Medical Officer of Aidoc. “I’m proud that Aidoc’s FDA-cleared AI solutions for flagging pulmonary embolism, cervical spine fractures, and intracranial hemorrhage are in full clinical use, saving lives in more than 300 medical centers across the world.”

Other FDA News of Interest

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access.

RapidAI Secures FDA Clearance for Perfusion Imaging in the Angiography Suite

“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow™ by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy